{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T16:06:56Z","timestamp":1791994016419,"version":"4.4.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012774","name":"Innovationsfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013856","name":"Debbie's Dream Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"Horizon 2020 Framework Programme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001732","name":"Danmarks Grundforskningsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007601","name":"Horizon 2020","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010665","name":"H2020 Marie Sk\u0142odowska-Curie Actions","doi-asserted-by":"publisher","award":["814244"],"award-info":[{"award-number":["814244"]}],"id":[{"id":"10.13039\/100010665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.biopha.2022.113842","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T13:43:47Z","timestamp":1665582227000},"page":"113842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["Does receptor balance matter? \u2013 Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models"],"prefix":"10.1016","volume":"156","author":[{"given":"A.T.","family":"Larsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.E.","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Sonne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bredtoft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MA","family":"Karsdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Henriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2022.113842_bib1","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/s41574-019-0176-8","article-title":"Obesity: global epidemiology and pathogenesis","volume":"15","author":"Bl\u00fcher","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.biopha.2022.113842_bib2","doi-asserted-by":"crossref","first-page":"E875","DOI":"10.1503\/cmaj.191707","article-title":"Obesity in adults: A clinical practice guideline","volume":"192","author":"Wharton","year":"2020","journal-title":"Cmaj"},{"key":"10.1016\/j.biopha.2022.113842_bib3","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s13300-020-00816-y","article-title":"Drug therapy in obesity: a review of current and emerging treatments","volume":"11","author":"Williams","year":"2020","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.biopha.2022.113842_bib4","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","article-title":"Anti-obesity drug discovery: advances and challenges","volume":"21","author":"M\u00fcller","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2022.113842_bib5","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1210\/en.2006-0393","article-title":"Antiobesity effects of the \u03b2-cell hormone amylin in diet-induced obese rats: Effects on food intake, body weight, composition, energy expenditure, and gene expression","volume":"147","author":"Roth","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.biopha.2022.113842_bib6","article-title":"Sustained reduction in food intake and body weight in high-fat-fed rats during 28-day amylin infusion","volume":"52","author":"Mack","year":"2003","journal-title":"Diabetes"},{"key":"10.1016\/j.biopha.2022.113842_bib7","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2174\/1381612013397357","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control","volume":"7","author":"Weyer","year":"2001","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.biopha.2022.113842_bib8","doi-asserted-by":"crossref","first-page":"784","DOI":"10.2337\/diacare.26.3.784","article-title":"Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes","volume":"26","author":"Hollander","year":"2003","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2022.113842_bib9","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/j.1464-5491.2004.01319.x","article-title":"Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial","volume":"21","author":"Ratner","year":"2004","journal-title":"Diabet. Med."},{"key":"10.1016\/j.biopha.2022.113842_bib10","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.2337\/dc07-0589","article-title":"Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin","volume":"30","author":"Riddle","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2022.113842_bib11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/DDDT.S3225","article-title":"Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes.","volume":"2","author":"Ryan","year":"2008","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.biopha.2022.113842_bib12","first-page":"E620","article-title":"Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study","volume":"293","author":"Smith","year":"2007","journal-title":"Am. J. Physiol. Metab."},{"key":"10.1016\/j.biopha.2022.113842_bib13","doi-asserted-by":"crossref","DOI":"10.2337\/dc08-0029","article-title":"Sustained weight loss following 12-month pramlintide treatment as an adjunct to lifestyle intervention in obesity","volume":"31","author":"Smith","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.biopha.2022.113842_bib14","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1210\/jc.2006-2003","article-title":"Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study","volume":"92","author":"Aronne","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2022.113842_bib15","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/oby.2004.76","article-title":"Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients","volume":"12","author":"Hollander","year":"2004","journal-title":"Obes. Res."},{"key":"10.1016\/j.biopha.2022.113842_bib16","unstructured":"J. Skarbaliene, R.S. Hansen, (Zealand Pharma), Potent Anti-obesity Effects of Amylin Analogue ZP8396 in Combination with Semaglutide in DIO Rats, in: The Obesity Society Annual Meeting, Poster #372, 2021."},{"key":"10.1016\/j.biopha.2022.113842_bib17","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jmedchem.1c00565","article-title":"Development of cagrilintide, a long-acting amylin analogue","author":"Kruse","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2022.113842_bib18","doi-asserted-by":"crossref","unstructured":"L.M. John, T. Kruse, K. Raun, Preclinical Weight Loss Efficacy of AM833 in Combination With Semaglutide in Rodent Models of Obesity, in: Preclin. Weight Loss Effic. AM833 Comb. With Semaglutide Rodent Model. Obes., P01\u201339 at ENDO 2021, 2021: pp. P01\u201339. https:\/\/doi.org\/10.1210\/jendso\/bvab048.108.","DOI":"10.1210\/jendso\/bvab048.108"},{"key":"10.1016\/j.biopha.2022.113842_bib19","article-title":"Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, dose-finding phase 2 trial","volume":"6736","author":"Lau","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113842_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0140-6736(21)00845-X","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial","volume":"397","author":"Enebo","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113842_bib21","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/S0140-6736(21)01999-1","article-title":"Long-acting amylin analogue for weight reduction","volume":"398","author":"Gadde","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113842_bib22","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(21)00944-2","article-title":"Cagrilintide plus semaglutide for obesity management","volume":"397","author":"Becerril","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2022.113842_bib23","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1124\/jpet.121.000567","article-title":"AM833 is a novel agonist of calcitonin family G protein\u2013coupled receptors: pharmacological comparison with six selective and nonselective agonists","volume":"377","author":"Fletcher","year":"2021","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2022.113842_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0092042","article-title":"Prolonged calcitonin receptor signaling by salmon, but not human calcitonin, reveals ligand bias","volume":"9","author":"Andreassen","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2022.113842_bib25","doi-asserted-by":"crossref","DOI":"10.1152\/ajpendo.00514.2015","article-title":"KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight.","author":"Gydesen","year":"2016","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2022.113842_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2021.101282","article-title":"KBP-066A, a long-acting dual amylin and calcitonin receptor agonist, induces weight loss and improves glycemic control in obese and diabetic rats","volume":"53","author":"Andreassen","year":"2021","journal-title":"Mol. Metab."},{"key":"10.1016\/j.biopha.2022.113842_bib27","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1124\/jpet.119.263392","article-title":"The calcitonin receptor plays a major role in glucose regulation as a function of dual amylin and calcitonin receptor agonist therapy","volume":"374","author":"Larsen","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2022.113842_bib28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1124\/jpet.119.257576","article-title":"The dual amylin and calcitonin receptor agonist KBP-088 induces weight loss and improves insulin sensitivity superior to chronic amylin therapy","volume":"370","author":"Larsen","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2022.113842_bib29","doi-asserted-by":"crossref","DOI":"10.1152\/ajpendo.00121.2014","article-title":"A novel oral dual amylin and calcitonin receptor agonist (KBP-042) exerts antiobesity and antidiabetic effects in rats.","volume":"307","author":"Andreassen","year":"2014","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.biopha.2022.113842_bib30","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.117.241281","article-title":"The dual amylin- and calcitonin receptor agonist kbp-042 works as adjunct to metformin on fasting hyperglycaemia and hba1c in a rat model of type 2 diabetes","author":"Hjuler","year":"2017","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2022.113842_bib31","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/bph.13723","article-title":"A novel dual amylin and calcitonin receptor agonist, KBP-089, induces weight loss through a reduction in fat, but not lean mass, while improving food preference","volume":"174","author":"Gydesen","year":"2017","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113842_bib32","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1177\/0192623315596857","article-title":"An investigative study of pancreatic exocrine biomarkers, histology, and histomorphometry in male Zucker Diabetic Fatty (ZDF) rats given dulaglutide by subcutaneous injection twice weekly for 13 weeks","volume":"43","author":"Usborne","year":"2015","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.biopha.2022.113842_bib33","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.molmet.2018.09.009","article-title":"LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept","volume":"18","author":"Coskun","year":"2018","journal-title":"Mol. Metab."},{"key":"10.1016\/j.biopha.2022.113842_bib34","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1124\/pr.115.010629","article-title":"Amylin: pharmacology, physiology, and clinical potential","volume":"67","author":"Hay","year":"2015","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.biopha.2022.113842_bib35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bph.14075","article-title":"Update on the pharmacology of calcitonin\/CGRP family of peptides: IUPHAR Review 25","volume":"175","author":"Hay","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2022.113842_bib36","first-page":"E821","article-title":"KBP-088, a novel DACRA with prolonged receptor activation, is superior to davalintide in terms of efficacy on body weight","volume":"310","author":"Gydesen","year":"2016","journal-title":"Am. J. Physiol. Metab."},{"key":"10.1016\/j.biopha.2022.113842_bib37","doi-asserted-by":"crossref","first-page":"R1855","DOI":"10.1152\/ajpregu.00297.2007","article-title":"Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight.","volume":"293","author":"Mack","year":"2007","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.biopha.2022.113842_bib38","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0196-9781(02)00022-0","article-title":"Acute 3rd-ventricular amylin infusion potently reduces food intake but does not produce aversive consequences","volume":"23","author":"Rushing","year":"2002","journal-title":"Peptides"},{"key":"10.1016\/j.biopha.2022.113842_bib39","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/0031-9384(95)02067-5","article-title":"Amylin decreases meal size in rats","volume":"58","author":"Lutz","year":"1995","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.biopha.2022.113842_bib40","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1002\/oby.21563","article-title":"The dual amylin- and calcitonin-receptor agonist kbp-042 increases insulin sensitivity and induces weight loss in rats with obesity","volume":"24","author":"Hjuler","year":"2016","journal-title":"Obesity"},{"key":"10.1016\/j.biopha.2022.113842_bib41","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1124\/jpet.119.263400","article-title":"Dose frequency optimization of the dual amylin and calcitonin receptor agonist KBP-088 \u2013 long-lasting improvement of food preference and body weight loss","volume":"373","author":"Larsen","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2022.113842_bib42","series-title":"Handb. Exp. Pharmacol.","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/978-3-642-24716-3_10","article-title":"Effects of amylin on eating and adiposity","author":"Lutz","year":"2012"},{"key":"10.1016\/j.biopha.2022.113842_bib43","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1046\/j.1365-2982.2002.00311.x","article-title":"Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus","volume":"14","author":"Vella","year":"2002","journal-title":"Neurogastroenterol. Motil."},{"key":"10.1016\/j.biopha.2022.113842_bib44","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1463-1326.2011.01465.x","article-title":"Glucoregulatory effects and prolonged duration of action of davalintide: a novel amylinomimetic peptide","author":"Mack","year":"2011","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.biopha.2022.113842_bib45","doi-asserted-by":"crossref","first-page":"R250","DOI":"10.1152\/ajpregu.00337.2020","article-title":"The long-acting amylin\/calcitonin receptor agonist ZP5461 suppresses food intake and body weight in male rats","volume":"321","author":"Stein","year":"2021","journal-title":"Am. J. Physiol. Integr. Comp. Physiol."},{"key":"10.1016\/j.biopha.2022.113842_bib46","doi-asserted-by":"crossref","DOI":"10.1126\/science.abm9609","article-title":"A structural basis for amylin receptor phenotype","volume":"375","author":"Cao","year":"2022","journal-title":"Science (80-.)"},{"key":"10.1016\/j.biopha.2022.113842_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-27760-0","article-title":"Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation","volume":"13","author":"Deganutti","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2022.113842_bib48","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/oby.23371","article-title":"Benefits of weight loss of 10% or more in patients with overweight or obesity: a review","volume":"30","author":"Tahrani","year":"2022","journal-title":"Obesity"},{"key":"10.1016\/j.biopha.2022.113842_bib49","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41574-018-0118-x","article-title":"Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases","volume":"15","author":"Clemmensen","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.biopha.2022.113842_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12902-020-00678-2","article-title":"The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile","volume":"21","author":"Larsen","year":"2021","journal-title":"BMC Endocr. Disord."},{"key":"10.1016\/j.biopha.2022.113842_bib51","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1152\/ajpendo.00419.2016","article-title":"Optimization of tolerability and efficacy of dual amylin and calcitonin receptor agonist, KBP-089, through dose escalation and combination with a GLP-1 analogue","volume":"313","author":"Gydesen","year":"2017","journal-title":"Am. J. Physiol. - Endocrinol. Metab."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222012318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332222012318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T12:04:23Z","timestamp":1778241863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332222012318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":51,"alternative-id":["S0753332222012318"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113842","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does receptor balance matter? \u2013 Comparing the efficacies of the dual amylin and calcitonin receptor agonists cagrilintide and KBP-336 on metabolic parameters in preclinical models","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2022.113842","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"113842"}}